Baidu
map

ClinicalTrials.gov网站临床试验注册指导

2013-07-02 曾广翘 MedSci原创

    临床试验注册一直是医学文献、通俗媒体以及美国议会所关注的焦点问题。临床试验的注册库都属于网络数据库,收录临床试验的资料,兼有伦理和学术双重作用。这些注册库确保公众对目前正在开展或既往已开展项目的了解,从而发挥伦理作用;同时还可为研究人员、期刊编辑人员和审稿专家提供一些解读研究结果所需的背景资料;通过完整罗列各项临床试验的目录清单,还可提示研究人员对当前尚未

    临床试验注册一直是医学文献、通俗媒体以及美国议会所关注的焦点问题。临床试验的注册库都属于网络数据库,收录临床试验的资料,兼有伦理和学术双重作用。这些注册库确保公众对目前正在开展或既往已开展项目的了解,从而发挥伦理作用;同时还可为研究人员、期刊编辑人员和审稿专家提供一些解读研究结果所需的背景资料;通过完整罗列各项临床试验的目录清单,还可提示研究人员对当前尚未发表成果的课题加以注意。各类试验注册库因主办机构、侧重面 (综合库还是疾病专库) 以及所收录试验信息内容等多种标准不同而彼此有别。国际医学期刊编辑委员会 (ICMJE) 等多个团体均主张注册库应实行非盈利机构管理、对注册户和用户免费开放等原则。试验注册库有别于研究成果库:前者收录的通常是研究方案和研究对象招募情况,而后者则收录研究结果。      目前,国际上能符合ICMJE原则的最大临床试验注册库就是美国的ClinicalTrials.gov网站,包含了约135 000项试验;还有英国的国际标准随机对照试验项目编号登记库,约有试验5050项。本文着重谈谈在

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2014-05-20 yengcb

    非常有用!谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2014-06-15 zhzhxiang
  4. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2013-12-11 仁医06
  5. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2013-07-05 wj68happy

    渴望已久了,对我有很大帮助!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2013-07-04 zll0628
  7. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2013-07-04 zhyy93
  8. [GetPortalCommentsPageByObjectIdResponse(id=9542, encodeId=f1c09542a2, content=非常有用!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea988211, createdName=yengcb, createdTime=Tue May 20 20:12:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952285, encodeId=f56119522854e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Thu Jun 05 02:25:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056938, encodeId=548820569387e, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 15 18:25:00 CST 2014, time=2014-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860954, encodeId=3c07186095473, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 11 02:25:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5862, encodeId=e56658621e, content=渴望已久了,对我有很大帮助! <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ac817620, createdName=wj68happy, createdTime=Fri Jul 05 21:30:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507605, encodeId=6fb1150e605ef, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556701, encodeId=fe5b1556e012f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631315, encodeId=109d163131545, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Thu Jul 04 02:25:00 CST 2013, time=2013-07-04, status=1, ipAttribution=)]
    2013-07-04 feifers
Baidu
map
Baidu
map
Baidu
map